FULLY FUNDED & SUPPORTED GENEROUSLY BY MANAGEMENT19 May 2025 10:56
The Company will use the net proceeds of the Fundraising as working capital to support the continued commercial development of the EpiSwitch® product line through partnerships and collaborations with diagnostic and pharmaceutical companies and direct sales as appropriate.